Peripheral T-lymphocytes express WNT7A and its restoration in leukemia-derived lymphoblasts inhibits cell proliferation
BMC Cancer, 02/09/2012
Ochoa-Hernandez AB et al.
– To the knowledge of the authors, this is the first report evidencing quantitatively decreased WNT7A levels in leukemia-derived cells and that WNT7A restoration in T-lymphocytes inhibits cell proliferation. These results also support the possible function of WNT7A as a tumor suppressor gene as well as a therapeutic tool.
Analyzed peripheral blood mononuclear cells, sorted CD3 and CD19 cells, 4 leukemia-derived cell lines, and blood samples from 14 patients with Acute lymphoblastic leukemia (ALL), and 19 clinically healthy subjects
Reverse transcription followed by quantitative Real-time Polymerase chain reaction (qRT-PCR) analysis were performed to determine relative WNT7A expression
Restoration of WNT7a was done employing a lentiviral system and by using a recombinant human protein
Cell proliferation was measured by addition of WST-1 to cell cultures
WNT7a is mainly produced by CD3 T-lymphocytes, its expression decreases upon activation, and it is severely reduced in leukemia-derived cell lines, as well as in the blood samples of patients with ALL when compared with healthy controls (p [less than or equal to]0.001)
By restoring WNT7A expression in leukemia-derived cells, we were able to demonstrate that WNT7a inhibits cell growth
Similar effect was observed when a recombinant human WNT7a protein was used
Restoration of WNT7A expression in Jurkat cells did not activate the canonical Wnt/beta-catenin pathway
MDLinx connects healthcare professionals and patients to tomorrow's important medical news, while providing the pharmaceutical and healthcare industries with highly targeted interactive marketing, education, content, and medical research solutions.